Alamar Biosciences, Inc. (ALMR)Healthcare | Medical Devices | Fremont, United States | NasdaqGS
30.71 USD
-2.29
(-6.939%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 30.71 |
Hot Take ↕ | Aug. 22, 2026, 3:33 a.m. EDT
The immediate outlook is neutral due to a lack of clear directional momentum. While the stock recently rallied sharply from the mid-$20s to the mid-$30s, suggesting some buying interest, the statistical forecasting model offers no predictive edge, showing zero expected movement over the next 45 days with low confidence. This price action appears to be noise rather than a confirmed trend. Looking further ahead, the investment case remains unproven. The company is a pre-revenue biotech firm with no dividend history and negative earnings, resulting in a negative forward P/E and significant operating losses. Although revenue growth is reported at 82%, the absolute scale is tiny ($100M), and the balance sheet shows negative operating cash flow. The market has assigned a high valuation multiple (P/S of 23x) despite these fundamental weaknesses, indicating speculative pricing rather than a solid buy-and-hold thesis. Without a proven product pipeline or sustained profitability, the long-term rating stays neutral. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.190818 |
| AutoARIMA | 0.191687 |
| AutoETS | 0.191693 |
| AutoTheta | 0.284234 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 33% |
| H-stat | 4.25 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.403 |
| Excess Kurtosis | 0.67 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 16.431 |
| Revenue per Share | 4.242 |
| Market Cap | 2,131,051,904 |
| Forward P/E | -56.61 |
| Profit Margins | -49.45% |
| Website | https://alamarbio.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.5 |
| Address1 | 47,071 Bayside Parkway |
| All Time High | 38.54 |
| All Time Low | 18.85 |
| Ask | 39.25 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 320,600 |
| Average Daily Volume3 Month | 325,427 |
| Average Volume | 325,427 |
| Average Volume10Days | 320,600 |
| Bid | 30.62 |
| Bid Size | 1 |
| Book Value | 4.509 |
| City | Fremont |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 30.71 |
| Current Ratio | 11.852 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 33.54 |
| Day Low | 30.455 |
| Debt To Equity | 16.431 |
| Display Name | Alamar Biosciences |
| Earnings Timestamp | 1,786,392,000 |
| Earnings Timestamp End | 1,793,881,800 |
| Earnings Timestamp Start | 1,793,881,800 |
| Ebitda | -37,483,000 |
| Ebitda Margins | -0.37326 |
| Enterprise To Ebitda | -51.554 |
| Enterprise To Revenue | 19.243 |
| Enterprise Value | 1,932,405,888 |
| Eps Current Year | -1.16399 |
| Eps Forward | -0.54245 |
| Eps Trailing Twelve Months | -0.67 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | (510) 605-5062 |
| Fifty Day Average | 27.7956 |
| Fifty Day Average Change | 2.9143982 |
| Fifty Day Average Change Percent | 0.10485106 |
| Fifty Two Week Change Percent | 50.0 |
| Fifty Two Week High | 38.54 |
| Fifty Two Week High Change | -7.830002 |
| Fifty Two Week High Change Percent | -0.20316559 |
| Fifty Two Week Low | 18.85 |
| Fifty Two Week Low Change | 11.859999 |
| Fifty Two Week Low Change Percent | 0.62917763 |
| Fifty Two Week Range | 18.85 - 38.54 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,776,432,600,000 |
| Float Shares | 36,164,734 |
| Forward Eps | -0.54245 |
| Forward P E | -56.61351 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 286 |
| Fullday Change | -2.29 |
| Fullday Change Percent | -6.9394 |
| Fullday Price | 30.71 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.58664 |
| Gross Profits | 58,910,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.21424 |
| Held Percent Institutions | 0.58101004 |
| Implied Shares Outstanding | 69,392,766 |
| Industry | Medical Devices |
| Industry Disp | Medical Devices |
| Industry Key | medical-devices |
| Ipo Expected Date | 2,026-04-17 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases. The company develops NULISA technology, a proteomics platform that detects and quantifies protein biomarkers. It offers ARGO high throughput (HT) System, a fully automated precision proteomics platform, performs ultra-high sensitivity and multiplexed analysis to support biomarker analysis across the continuum of discovery, translational research and ultimately, and diagnostics. The company's offering is utilized in research areas including immunology, neurology, and oncology. It serves global research and academic institutions, biopharmaceutical companies, contract research organizations, and service labs. The company operates in the United States, rest of Europe, Middle East and Africa, Germany, Asia Pacific, and internationally. It has a strategic partnership with Alzheimer's Disease Data Initiative, and Gates Ventures to advance translational research in alzheimer's disease. The company was incorporated in 2018 and is based in Fremont, California. |
| Long Name | Alamar Biosciences, Inc. |
| Market | us_market |
| Market Cap | 2,131,051,904 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_1680636437 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -49,661,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,289,267,350 |
| Number Of Analyst Opinions | 5 |
| Open | 32.7 |
| Operating Cashflow | -60,327,000 |
| Operating Margins | -0.45985 |
| Payout Ratio | 0.0 |
| Phone | (510) 626-9888 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 30.71 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 33.0 |
| Price Eps Current Year | -26.383387 |
| Price Hint | 2 |
| Price To Book | 6.810823 |
| Price To Sales Trailing12 Months | 21.22139 |
| Profit Margins | -0.49453 |
| Quick Ratio | 9.671 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -2.29 |
| Regular Market Change Percent | -6.9394 |
| Regular Market Day High | 33.54 |
| Regular Market Day Low | 30.455 |
| Regular Market Day Range | 30.455 - 33.54 |
| Regular Market Open | 32.7 |
| Regular Market Previous Close | 33.0 |
| Regular Market Price | 30.71 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 267,636 |
| Revenue Growth | 0.821 |
| Revenue Per Share | 4.242 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 69,392,766 |
| Shares Percent Shares Out | 0.0299 |
| Shares Short | 2,075,441 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 2,245,722 |
| Short Name | Alamar Biosciences, Inc. |
| Short Percent Of Float | 0.048499998 |
| Short Ratio | 7.09 |
| Source Interval | 15 |
| State | CA |
| Symbol | ALMR |
| Target High Price | 35.0 |
| Target Low Price | 31.0 |
| Target Mean Price | 33.4 |
| Target Median Price | 34.0 |
| Total Cash | 250,052,000 |
| Total Cash Per Share | 3.603 |
| Total Debt | 51,406,000 |
| Total Revenue | 100,420,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.67 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 25.256739 |
| Two Hundred Day Average Change | 5.4532604 |
| Two Hundred Day Average Change Percent | 0.21591309 |
| Type Disp | Equity |
| Volume | 267,636 |
| Website | https://alamarbio.com |
| Zip | 94,538 |